Cancer
Researchers from Chongqing Medical University in China have made a significant discovery in the field of cancer immunotherapy. A new report published in Advanced Healthcare Materials reveals that a novel metal-polyphenol network-coated human serum albumin nanoplatform, dubbed IMT@H, has shown remarkable efficacy in treating HPV-associated malignancies. The nanovaccine combination
Immunotherapy
Researchers from Hunan University in Changsha, People's Republic of China, have made a groundbreaking discovery in the treatment of spinal cord injuries. They have developed a new hydrogel that can modulate microglia/macrophage polarization, leading to significant improvements in function recovery after spinal cord injury. The study, published
Cancer research
A groundbreaking study on cancer therapy has revealed a promising approach to augment existing immunotherapies. Researchers at AbbVie Inc. demonstrated that inhibiting TAK1 in tumor cells makes them more susceptible to cytotoxic T cells, thus sensitizing them to TNF-a-induced cytotoxicity. This novel approach leverages the cytotoxic capacity of TNF to
Immunotherapy
Researchers from Hunan University in Changsha, People's Republic of China, have made a groundbreaking discovery in the treatment of spinal cord injuries. They have developed a new hydrogel that can modulate microglia/macrophage polarization, leading to significant improvements in function recovery after spinal cord injury. The study, published
Cancer
Research conducted at the Chinese Academy of Sciences has unveiled a promising new approach to cancer treatment using artificial intelligence to design excipient-free nanomedicine. The study, led by Haijun Yu, utilized a deep learning platform called Gramord to rationally design nanoparticles capable of achieving combination therapeutic effects. The platform identified
Cancer research
Researchers at the Department of Medical Imaging in Guangzhou, China, have made a groundbreaking discovery in cancer therapy. By combining immunogenic cell death induction with STING pathway activation, they have developed a multifunctional nanoplatform that enhances cancer immunotherapy. This innovative approach has shown promise in promoting dendritic cell maturation and
Cancer
In a groundbreaking study published in the journal Molecular and Cellular Biochemistry, researchers from Zunyi Medical University and colleagues have discovered a novel approach to treating gastric cancer using histone lysine-specific demethylase 1 (LSD1) inhibitors. According to the study, LSD1 knockdown boosts T cell-mediated anti-tumor immunity in gastric cancer by
Cancer treatment
Vinmec International Hospital, a leading healthcare provider in Vietnam, has gained international recognition for its innovative approach to cancer treatment using autologous cell-based AIET immunotherapy. This technology, transferred from GN Corporation, Japan, has been implemented in accordance with Japanese regulations and has resulted in significantly extended survival and improved quality
Cancer
Research from the Department of Pathology and the Federal University of Minas Gerais has shed new light on the potential of lipid nanoparticle-based approaches in advancing cancer immunotherapy. According to the study, lipid nanoparticles offer promising solutions to overcome challenges in cancer treatment, including production, systemic toxicity, and inefficient delivery.
Immunotherapy
Researchers at the First Affiliated Hospital of Xiamen University in Fujian, People's Republic of China, have discovered a novel prognostic subgroup in ovarian cancer patients characterized by low Siglec15 and high PD-L1 expression. This subgroup exhibited improved overall survival compared to other subgroups, with a more active immune
Cancer prevention
A new study conducted at the Catholic University of Korea, in collaboration with Seoul St. Mary's Hospital, has shed light on the role of cancer-associated fibroblasts in the ovarian cancer microenvironment. According to the research, cancer-associated fibroblasts (CAFs) contribute to immunosuppression in ovarian cancer by upregulating indoleamine 2,
Cancer
The American Association for Cancer Research (AACR), the National Cancer Institute (NIC), and the European Organisation for Research and Treatment of Cancer (EORTC) hosted the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. MAIA Biotechnology's Sr. Medical Director, Victor Zaporojan, presented a Trial in Progress poster
